Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy Post published:February 8, 2022 Post category:Press Release
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada Post published:February 8, 2022 Post category:Press Release
MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial Post published:February 8, 2022 Post category:Press Release
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility Post published:February 7, 2022 Post category:Press Release
Optimi Health Dealer’s License Granted by Health Canada Post published:February 7, 2022 Post category:Press Release
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides Post published:February 3, 2022 Post category:Press Release
Entheon Biomedical Announces the Approval of DMT Clinical Trial Post published:February 3, 2022 Post category:Press Release
MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform Post published:February 3, 2022 Post category:Press Release
Psyched Wellness Announces Additional Positive Results from the 14-day Oral Toxicity Study of AME-1 Post published:February 3, 2022 Post category:Press Release
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds Post published:February 3, 2022 Post category:Press Release